Risk factors

Contineum Therapeutics (CTNM) risk factors

Item 1A of every Contineum Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open CTNM in Gloom →
Contineum Therapeutics' chart, financials and news, free in your browser.Open CTNM in Gloom →
  • FY2025 10-K risk factors
    67 risks8 new15 dropped15 reworded

    Contineum Therapeutics highlighted new regulatory hurdles for drug candidates PIPE-791 and PIPE-307.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors
    74 risks

    Contineum Therapeutics faces heavy concentration risks on its lead drug candidates PIPE-791 and PIPE-307. The company relies heavily on third-party manufacturers, clinical research organizations, and its J&J collaboration agreement.

    Filed Mar 06, 2025